Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Non-Current Deffered Revenue (2024 - 2026)

Kura Oncology has reported Non-Current Deffered Revenue over the past 3 years, most recently at $416.7 million for Q1 2026.

  • Quarterly Non-Current Deffered Revenue rose 53.26% to $416.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $416.7 million through Mar 2026, up 53.26% year-over-year, with the annual reading at $424.9 million for FY2025, 67.35% up from the prior year.
  • Non-Current Deffered Revenue was $416.7 million for Q1 2026 at Kura Oncology, down from $424.9 million in the prior quarter.
  • Over five years, Non-Current Deffered Revenue peaked at $424.9 million in Q4 2025 and troughed at $252.5 million in Q2 2025.
  • The 3-year median for Non-Current Deffered Revenue is $270.4 million (2025), against an average of $314.8 million.
  • Year-over-year, Non-Current Deffered Revenue surged 67.35% in 2025 and then skyrocketed 53.26% in 2026.
  • A 3-year view of Non-Current Deffered Revenue shows it stood at $253.9 million in 2024, then surged by 67.35% to $424.9 million in 2025, then decreased by 1.92% to $416.7 million in 2026.
  • Per Business Quant, the three most recent readings for KURA's Non-Current Deffered Revenue are $416.7 million (Q1 2026), $424.9 million (Q4 2025), and $268.9 million (Q3 2025).